Diligence memo · auto-generated · as of July 2, 2026
Alixia, Inc.
Alixia, Inc. looks under-valued against its niche peers and is quiet on financing cadence.
Businessfiled
Alixia, Inc. operates in Biotechnology, based in SAN FRANCISCO, CA, USA. Targeting the Tumor Ecosystem to address cancer drug resistance.
Sub-sector tags: Biotech, Therapeutics, Drug discovery, Oncology, Biotechnology.
Capital & rounds (filed)filed
Alixia, Inc. has raised $1.8M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).
Largest single filing: $1.8M on 2024-07-09.
Most recent recorded round closed around 2024-07-09.
Valuation (modeled)modeled
Provath models Alixia, Inc. at approximately $8.7M (range $1.3M–$23M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.61× the median modeled value of Seed Biotechnology companies in 2022–2024 (207 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Last raise 24 mo ago; this sector typically re-raises about every 14 months.
Slightly overdue versus sector cadence.
Comparablesmixed
Capital scale ranks ahead of 26% of Biotechnology peers (4293 compared).
Modeled value ranks above 17% of those peers.
Closest niche peers: Mesentech Inc., Marlinspike Therapeutics, Inc., Microbial Machines, Inc., Pearl Diagnostics, Inc., Crossfire Medical Inc.
Peoplefiled
3 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.